GRAIL Inc. (NASDAQ: GRAL) shares surged roughly 35% on September 21 after newly released U.S. Food and Drug Administration briefing documents intensified expectations around the regulatory review of Galleri, the company’s multi-cancer early detection blood test. The FDA’s Molecular and Clinical Genetics Panel is scheduled to meet on September 23 to discuss and vote on GRAIL’s premarket approval application, putting one of the most ambitious cancer-screening technologies currently before U.S. regulators into a potentially decisive week. Galleri is designed for adults aged 50 and older and uses next-generation sequencing to identify cancer-associated methylation patterns in cell-free DNA collected through a standard blood draw.
GRAL finished Monday near $108 after gaining approximately 35%, its strongest single trading session in more than a year, as investors reacted to the tone of the FDA materials. Reuters reported that agency reviewers had not identified outstanding questions for the advisory committee concerning Galleri’s analytical performance, study design or primary safety analyses, although important questions remain about how its effectiveness should be characterized and communicated. The rally also propelled GRAIL into unusually intense retail-investor attention ahead of Wednesday’s meeting, where the panel will formally consider safety, effectiveness and whether Galleri’s probable benefits outweigh its probable risks.
Why did GRAIL stock jump almost 35% before the FDA Galleri meeting?
The market reaction reflects the difference between an FDA briefing package dominated by fundamental objections and one that instead concentrates debate on interpretation, labeling and benefit-risk considerations. The agency’s executive summary confirms that Galleri’s application is supported principally by the PATHFINDER 2 study in North America and the much larger NHS-Galleri randomized study in England, while the FDA is asking outside experts whether the combined evidence provides reasonable assurance that the test is safe and effective for its proposed use. The panel will also vote separately on whether Galleri’s benefits outweigh its risks for adults aged 50 and older.
That does not mean FDA approval is assured. Advisory committees provide recommendations rather than binding regulatory decisions, and the agency can ultimately reach a different conclusion after considering the panel’s vote, additional application material and any remaining questions. GRAIL has said the company expects an FDA decision during the first part of 2027, making Wednesday’s meeting a critical milestone rather than the final regulatory event.
Investor enthusiasm is especially striking because GRAL experienced a very different reaction earlier this year. Shares lost roughly half their value after the headline results from NHS-Galleri showed that the trial failed its combined primary endpoint involving Stage III and Stage IV cancers across the prespecified group of 12 cancer types. The September rally therefore represents a major reassessment of how investors are interpreting the broader evidence now being evaluated by regulators rather than a reversal of the underlying trial result itself.
What exactly does the Galleri blood test do?
Galleri is a prescription-only in vitro diagnostic designed to search circulating cell-free DNA for abnormal methylation patterns associated with cancer. Machine-learning classifiers analyze the sequencing information to determine whether a cancer signal is present and, when one is detected, predict the likely anatomical origin of that signal to help physicians direct subsequent diagnostic testing. GRAIL’s proposed indication covers screening adults aged 50 years and older for multiple cancer types before symptoms emerge.
The test is not designed to diagnose cancer by itself. A positive Galleri result requires established diagnostic procedures such as imaging, biopsy or other testing, while a negative result does not exclude the possibility that cancer is present. The FDA materials specifically state that patients should continue guideline-recommended single-cancer screening and that Galleri should not replace established approaches such as mammography, colonoscopy or appropriate lung and cervical cancer screening.
The potential attraction comes from the enormous screening gap beyond those established programs. FDA reviewers noted that approximately 58% of the nearly 630,000 cancer deaths expected in the United States during 2026 are attributable to cancers for which there is no U.S. Preventive Services Task Force Grade A, B or C screening recommendation. A blood test capable of identifying signals from multiple cancers could therefore potentially supplement existing screening by reaching diseases that are often discovered only after symptoms develop.
How well did Galleri perform in the U.S. PATHFINDER 2 study?
The FDA’s analysis of the PATHFINDER 2 dataset reported 12-month episode sensitivity of 35.0%, meaning Galleri identified a cancer signal in about 35% of cancers diagnosed within the relevant follow-up period in the analyzed population. Specificity was 99.85%, positive predictive value was 77.0% and negative predictive value was 99.07%. In practical terms, the high specificity means comparatively few people without a subsequently diagnosed cancer received a positive signal, while sensitivity shows that Galleri still missed a substantial proportion of cancers.
The positive predictive value is particularly relevant because multi-cancer screening can create downstream testing if false-positive results are common. In the FDA’s PATHFINDER 2 analysis, 106 of 138 weighted cancer-signal-positive results corresponded to a cancer diagnosis within 12 months. GRAIL’s sponsor materials also reported Cancer Signal Origin accuracy above 90%, indicating that when Galleri correctly identified cancer, it frequently pointed clinicians toward the appropriate anatomical location for further evaluation.
A broader analysis of the complete 35,878-participant PATHFINDER 2 cohort presented by GRAIL at the American Society of Clinical Oncology annual meeting found that adding Galleri to recommended breast, cervical, colorectal and lung screening increased the number of cancers detected through screening by approximately 6.5 times. GRAIL reported that 53% of newly detected cancers identified by Galleri were Stage I or II and approximately 71% were Stage I through III. Those company-reported analyses support the argument that Galleri can expand the reach of cancer screening, although the FDA’s review appropriately focuses on both cancers detected and cancers missed.
Why does the failed NHS-Galleri primary endpoint still matter?
The NHS-Galleri trial enrolled more than 142,000 asymptomatic adults aged 50 to 77 and is especially important because it tested annual Galleri screening against standard care in a randomized population rather than simply measuring test performance among participants known to have cancer. The study was designed to determine whether annual testing could reduce diagnoses of Stage III and Stage IV cancers among 12 prespecified cancer types responsible for a large proportion of cancer mortality. On that primary endpoint, the trial did not demonstrate a statistically significant reduction.
After three screening rounds, combined Stage III and Stage IV incidence in the intervention group was approximately 3% higher than in controls for the 12 prespecified cancers, with an incidence rate ratio of 1.03 and a p-value of 0.6324. That primary endpoint failure caused the severe GRAL sell-off earlier in 2026 because shifting diagnoses away from advanced disease has long been regarded as one of the clearest potential clinical benefits of multi-cancer screening. GRAIL argued that interpretation was complicated by an increase in Stage III diagnoses during the first screening round, when previously undiagnosed cancers already present in the population were uncovered.
Secondary results were more encouraging. Stage IV diagnoses in the 12-cancer group were 14% lower overall, with reductions of 22% during the second screening round and 26% during the third round, while Stage I and II diagnoses increased 16% after three rounds. Because the primary endpoint failed, those secondary findings cannot simply be treated as replacing it, but they form an important part of the benefit-risk argument now before the advisory panel.
What concerns does the FDA still have about calling Galleri an early-detection test?
The regulatory debate is partly about what clinicians and patients should infer from a negative or positive Galleri result. Although specificity is extremely high, overall sensitivity remains much lower and varies substantially across cancer type and disease stage. FDA materials emphasize that a negative Galleri result does not rule out cancer, creating a need for careful labeling so patients do not abandon established screening or delay investigation of concerning symptoms.
The agency is also asking the advisory panel to consider how test performance should be communicated given differences among cancers. Some aggressive cancers shed more detectable cell-free DNA into the bloodstream, whereas several early-stage or slower-growing cancers may be substantially harder for blood-based testing to identify. For example, the FDA’s detailed analysis shows low Stage I sensitivity for some cancer categories, illustrating why a general claim about “early detection” can mask considerable variation in what the test actually detects.
This distinction could influence the eventual product label even if Galleri receives approval. The FDA’s questions explicitly seek advice on appropriate warnings, risk mitigation and communication of benefits, risks and limitations to support shared decision-making between patients and healthcare providers. The panel is also being asked whether additional post-approval studies should be required to generate more information about the long-term benefits and risks of repeat Galleri screening.
How significant are the safety risks from false-positive Galleri results?
Unlike a therapeutic drug, Galleri does not directly expose a patient to pharmacological toxicity, but screening carries a different category of risk. A false-positive cancer signal can lead to imaging, endoscopy, biopsy or other diagnostic procedures that may create physical complications, financial costs and anxiety, while a false-negative result could produce inappropriate reassurance. FDA reviewers specifically identify these downstream consequences as part of the benefit-risk assessment.
The available trial data nevertheless suggest direct safety events have been relatively uncommon. In PATHFINDER 2, less than 1% of consented participants experienced a study-related adverse event during the 12-month follow-up period, with most related to routine blood collection, while anxiety after a positive signal generally returned toward baseline over time. The NHS-Galleri study similarly reported no serious procedure- or device-related adverse events among more than 142,000 participants in the relevant analysis.
The more difficult policy question is therefore not whether drawing blood is dangerous, but whether the cancers found justify the false positives, missed cancers and downstream diagnostic work created by population-scale screening. That is precisely why the FDA is asking its advisers to vote independently on safety, effectiveness and overall benefit versus risk rather than treating analytical accuracy as sufficient evidence on its own.
How big is the commercial opportunity if Galleri wins FDA approval?
Galleri is already commercially available in the United States as a laboratory-developed test, despite not having FDA marketing authorization. GRAIL reported first-half 2026 Galleri revenue of $82.5 million, up 30% year over year, while test volume rose 42% to more than 117,000. The company recorded a second-quarter net loss of $110.2 million, underscoring how important broader adoption and reimbursement could become to its path toward a sustainable commercial model.
FDA approval would not automatically guarantee widespread insurance reimbursement, but it could materially change the commercial environment. GRAIL currently has coverage arrangements with selected employers and health plans, yet it does not have broad Medicare or major commercial-insurer reimbursement. Its regulatory filings state that the company is pursuing FDA approval in part to support broader access to Galleri across the United States.
The company is also building international ambitions around the technology. GRAIL completed a $110 million equity financing with Samsung C&T Corporation and Samsung Electronics in June, alongside plans to collaborate on potential Galleri commercialization in South Korea and potentially additional Asian markets including Japan and Singapore, subject to regulatory approvals. That financing provides additional capital while simultaneously linking Galleri to a potential international distribution strategy if regulatory validation strengthens.
What happens to GRAL stock after the September 23 FDA panel?
The immediate catalyst is unusually clear. The FDA panel will vote on whether Galleri provides reasonable assurance of safety, whether it provides reasonable assurance of effectiveness and whether its benefits outweigh its risks for the proposed population. Those votes are non-binding, but they could substantially influence market expectations for the FDA’s eventual PMA decision.
That setup explains why GRAL has become such a volatile healthcare stock. Investors watched the company lose nearly half its value after the NHS-Galleri primary endpoint disappointment and then witnessed a roughly 35% single-day rally when FDA documents appeared less restrictive than feared. Stocktwits described September 21 as the stock’s best day in more than a year and a half, illustrating the extent to which retail attention has converged on Wednesday’s regulatory event.
The larger question extends well beyond one trading session. No device has yet received FDA authorization for screening multiple cancer types in the manner proposed for Galleri, according to the agency, so a successful regulatory outcome could establish an important precedent for an emerging diagnostics category. GRAIL must still persuade regulators that identifying additional cancers through a single blood test produces enough clinical benefit to justify missed cancers, false positives and additional diagnostic procedures, making the September 23 panel one of the most consequential diagnostics events of 2026.
